Logo do repositório
 

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

dc.contributor.authorGarcia, Karoline Soares
dc.contributor.authorFacas, Bianca Pocopetz
dc.contributor.authorMachado, Marta Brenner
dc.contributor.authorTeixeira, Fábio Vieira
dc.contributor.authorAvedano, Luisa
dc.contributor.authorLönnfors, Sanna
dc.contributor.authorHossne, Rogério Saad [UNESP]
dc.contributor.authorPeyrin-Biroulet, Laurent
dc.contributor.authorQueiroz, Natália Sousa Freitas
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionBrazilian Crohn’s Disease and Ulcerative Colitis Association (Associação Brasileira de Colite Ulcerativa e Doença de Crohn: ABCD)
dc.contributor.institutionGastrosaúde: IBD Clinic
dc.contributor.institutionEuropean Federation of Crohn’s and Ulcerative Colitis Association (EFCCA)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionNancy University Hospital
dc.date.accessioned2021-06-25T11:16:18Z
dc.date.available2021-06-25T11:16:18Z
dc.date.issued2021-01-01
dc.description.abstractBackground: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients. Methods: An online survey consisting of 19 questions was made available by the European Federation of Crohn’s and Ulcerative Colitis Associations between July 2018 and December 2018. Only respondents who had heard of biosimilars were asked to respond to all of the questions. Results: A total of 102 Brazilian IBD patients responded to the survey. The majority (78.4%) of patients had been exposed to anti-tumor-necrosis-factor drugs and 63.4% of them had heard of biosimilars. Brazilian respondents worried significantly more about biosimilars being less effective than the originator (62.5% versus 47.9%, p value 0.03) and molecular differences between biosimilars and originators (53.1% versus 31.8, p value 0.001) as compared with non-Brazilian IBD patients. The majority of Brazilian (75%) and non-Brazilian (64.1%) respondents thought that the lower cost of biosimilars should not come before their safety and efficacy (p value 0.09). In addition, 79.1% of Brazilian respondents believed that the arrival of biosimilars will have an impact on the management of IBD. Conclusions: Brazilian patients reported higher rates of misconceptions regarding biosimilars than non-Brazilian IBD patients. Although patients still worry about different aspects regarding biosimilars, they also tend to be confident that biosimilars will have an impact on the management of their disease. With the recent approval of many biosimilars in Brazil and the imminent widespread use of these drugs, our data raise awareness for the need of providing patient education to prevent negative expectations toward switching to biosimilars.en
dc.description.affiliationDepartment of Gastroenterology University of São Paulo School of Medicine, 255 Doutor Enéas de Carvalho Aguiar Avenue
dc.description.affiliationDepartment of Gastroenterology University of São Paulo School of Medicine
dc.description.affiliationDepartment of Gastroenterology Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) Brazilian Crohn’s Disease and Ulcerative Colitis Association (Associação Brasileira de Colite Ulcerativa e Doença de Crohn: ABCD)
dc.description.affiliationGastrosaúde: IBD Clinic
dc.description.affiliationEuropean Federation of Crohn’s and Ulcerative Colitis Association (EFCCA)
dc.description.affiliationPaulista State University (UNESP) Botucatu Medical School
dc.description.affiliationDepartment of Gastroenterology Nancy University Hospital
dc.description.affiliationUnespPaulista State University (UNESP) Botucatu Medical School
dc.identifierhttp://dx.doi.org/10.1177/17562848211013249
dc.identifier.citationTherapeutic Advances in Gastroenterology, v. 14.
dc.identifier.doi10.1177/17562848211013249
dc.identifier.issn1756-2848
dc.identifier.issn1756-283X
dc.identifier.scopus2-s2.0-85106056463
dc.identifier.urihttp://hdl.handle.net/11449/208691
dc.language.isoeng
dc.relation.ispartofTherapeutic Advances in Gastroenterology
dc.sourceScopus
dc.subjectadalimumab
dc.subjectbiosimilar
dc.subjectinflammatory bowel disease
dc.subjectinfliximab
dc.titleBiosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patientsen
dc.typeArtigo
dspace.entity.typePublication
unesp.author.orcid0000-0001-9990-5093[2]
unesp.author.orcid0000-0003-2857-0825[9]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentCirurgia e Ortopedia - FMBpt

Arquivos